Antizol

Antizol is a brand name of fomepizole, approved by the FDA in the following formulation(s):

ANTIZOL (fomepizole - injectable; injection)

• 
  Manufacturer: PALADIN LABS
  
  Approval date: December 4, 1997
  
  Strength(s): 1.5GM/1.5ML (1GM/ML) ^[RLD][AP]

Has a generic version of Antizol been approved?

A generic version of Antizol has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Antizol and have been approved by the FDA:

fomepizole injectable; injection

• 
  Manufacturer: BIONICHE PHARMA USA
  
  Approval date: April 7, 2009
  
  Strength(s): 1.5GM/1.5ML (1GM/ML) ^[AP]


• 
  Manufacturer: LUITPOLD
  
  Approval date: December 14, 2007
  
  Strength(s): 1.5GM/1.5ML (1GM/ML) ^[AP]


• 
  Manufacturer: NAVINTA LLC
  
  Approval date: March 6, 2008
  
  Strength(s): 1.5GM/1.5ML (1GM/ML) ^[AP]


• 
  Manufacturer: SYNERX PHARMA
  
  Approval date: March 3, 2008
  
  Strength(s): 1.5GM/1.5ML (1GM/ML) ^[AP]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Antizol. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Ultrapure 4-methylpyrazole
  Patent 7,553,863
  Issued: June 30, 2009
  Inventor(s): Reardan; Dayton T. & Combe; Michel D.
  Assignee(s): Paladin Labs (Barbados) Inc.
  Disclosed is an ultrapure 4-methylpyrazole containing less than 0.1% pyrazole and containing less than 10 ppm each of hydrazine and nitrobenzaldehyde. The ultrapure 4-methylpyrazole is prepared by a novel process so that less than 0.01% of ethylvinyl ether is present.
  
  Patent expiration dates:
  
  
  • June 30, 2027
    
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  

See also...

• Antizol Consumer Information (Cerner Multum)
• Antizol AHFS DI Monographs (ASHP)
• Fomepizole Consumer Information (Cerner Multum)
• Fomepizole AHFS DI Monographs (ASHP)